Levetiracetam Injection, Solution, Concentrate
Product Images NDC 68094-313

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 68094-313). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Precision Dose, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Image 01)

This text provides information about the number of patients in different treatment groups and the dosage of the drug Levetiracetam. Specifically, it mentions the number of patients in the Placebo group (95 patients), as well as the number of patients in two Levetiracetam dosage groups: 1,000 mg/day (97 patients) and 3,000 mg/day (101 patients).*

FDA Label Image

Figure 2 (Image 02)

This text shows the percentage of patients in a study who were given different doses of a medication called Levetiracetam. The doses evaluated are 1,000 mg/day and 2,000 mg/day. The text also mentions a placebo group with 111 patients. The percentages of patients for each dose level are not provided.*

FDA Label Image

Figure 3 (Image 03)

This text appears to be a table showing the percentage of patients in different groups. The groups are labeled as "Placebo" and "Levetiracetam 3,000 mg/day" with the respective sample sizes shown in parentheses. Unfortunately, the output does not provide any information about what the percentages represent or any additional data. Therefore, a more specific description or analysis cannot be provided.*

FDA Label Image

Figure 4 (Image 04)

This text provides data on the percentage of patients for a study involving a placebo and levetiracetam. The percentages range from 45% to 0%. The placebo group consisted of 97 patients with a percentage of 44.6% while the levetiracetam group had 101 patients, with the corresponding percentage not mentioned.*

FDA Label Image

Figure 5 (Image 05)

This text appears to be a table showing the percentages of patients in different groups. The table includes percentages ranging from 0% to 45%. The first column represents different percentage values, while the second column displays the corresponding group names. The group names mentioned are "Placebo" with a sample size (N) of 51, and "Levetiracetam" with a sample size (N) of 58.*

FDA Label Image

Figure 6 (Image 06)

This text provides information about the percentages of patients in two groups, Placebo and Levetiracetam. The percentages are 45.2% and 72.2%, respectively. However, due to the limited information provided, it is not possible to determine the context or purpose of these percentages.*

FDA Label Image

Principal Display Panel (100 mg/mL Vial Carton)

Description: This text appears to be a description of a medication. The medication is levetiracetam, which is used for intravenous use only. It comes in single-dose vials containing 500 mg of the medication. The vials need to be diluted before administration, and any unused portion should be discarded. The medication also contains sodium acetate trihydrate, sodium chloride, and acetic acid. The recommended dosage and storage instructions can be found in the package insert.*

FDA Label Image

Principal Display Panel (100 mg/mL Vial Carton)

FDA Label Image

Chemical Structure (Levetiracetam)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.